1. Phylogeny  
KSR1 is a member of the kinase suppressor of Ras (KSR) family, a group of proteins that is evolutionarily conserved from invertebrates to mammals. In invertebrate species such as Drosophila melanogaster, a single KSR protein has been identified, whereas in Caenorhabditis elegans and mammals two paralogs—KSR1 and KSR2—exist. This gene family, sharing a characteristic domain architecture (comprising regions CA1 through CA5), is phylogenetically related to the Raf kinase family, although modifications in the catalytic domain of KSR1 have resulted in its predominant function as a scaffold in higher organisms rather than a classical enzyme. Studies have demonstrated that the overall sequence conservation and conserved domain organization reflect an ancestral origin of KSR proteins in metazoans, with subsequent divergence that gave rise to tissue-specific isoforms and functional specialization observed in mammals (dougherty2009ksr2isa pages 1-2, neilsen2017ksrasa pages 3-4, muller2000identificationofbksr1 pages 1-2). In the context of the eukaryotic protein kinase superfamily, KSR1, by virtue of its retained kinase-like fold yet modified catalytic motifs, occupies a unique phylogenetic niche where its role in assisting the assembly of the Raf / MEK / ERK cascade is conserved despite the loss of robust catalytic activity compared to classical serine/threonine kinases (zhang2014identificationofksr1 pages 42-46).

2. Reaction Catalyzed  
When functioning in its catalytic capacity, KSR1 catalyzes the transfer of a phosphate group from ATP to specific serine or threonine residues on substrate proteins. The generalized chemical reaction is as follows:  
  ATP + [protein]-(L-serine or L-threonine) → ADP + [protein]-(L-serine/threonine)-phosphate + H⁺.  
Experimental studies, although sometimes yielding only low phosphorylation stoichiometry, have demonstrated that KSR1 is capable of autophosphorylation and can phosphorylate substrates such as Raf-1 under conditions where its kinase activity is detectable, thereby promoting subsequent activation of the MAPK cascade (zhang2014identificationofksr1 pages 49-52).

3. Cofactor Requirements  
In catalytic assays that evaluate KSR1 activity, the reaction buffer is typically supplemented with divalent cations; most notably, Mg²⁺ is included to facilitate proper ATP binding and phosphate transfer. This is consistent with the conventional requirement of serine/threonine kinases, wherein the coordination of Mg²⁺ with ATP plays a critical role in catalysis. Although KSR1 has been largely characterized as a scaffolding protein with uncertain kinase activity under physiological conditions, the in vitro detection of its catalytic function is predicated on the inclusion of Mg²⁺ (dar2016smallmoleculestabilization pages 6-7, zhang2014identificationofksr1 pages 49-52).

4. Substrate Specificity  
KSR1 exerts its function within the MAPK pathway by facilitating the efficient phosphorylation of key signaling proteins. Although the precise consensus substrate motif for KSR1 phosphorylation has not been fully delineated in the available literature, experimental evidence supports its ability to phosphorylate serine/threonine residues on proteins that are integral to the Raf / MEK / ERK signaling complex. Notably, studies have reported that KSR1 phosphorylates Raf-1 at critical regulatory sites (for example, phosphorylation events at residues such as Thr269 have been documented under certain stimulatory conditions) and contributes to MEK activation when present within the multi‐protein complex (zhang2014identificationofksr1 pages 49-52, neilsen2017ksrasa pages 21-22). Thus, while a detailed linear substrate motif is not established, KSR1 is functionally specific for substrates that serve as intermediates in Ras-dependent signal transduction.

5. Structure  
KSR1 is organized into several conserved domains that underpin both its scaffolding and potential catalytic functions. The protein contains five major conserved regions designated CA1 through CA5. The CA1 domain, unique to KSR proteins, is implicated in engaging specific binding partners and may contribute to regulation via protein–protein interactions. Next, the CA2 domain is characterized by a proline-rich sequence that likely serves as a flexible linker or site for docking regulatory factors. In the CA3 region, a cysteine-rich atypical C1 domain is present; this domain is essential for membrane association through specific lipid interactions and is critical for the spatial regulation of the MAPK cascade. The CA4 domain, enriched in serine and threonine residues, includes motifs that facilitate the binding of ERK and may influence the overall dynamics of the signaling complex. Finally, the CA5 region represents a kinase-like domain that resembles the catalytic domain of Raf kinases; however, key catalytic residues are altered (for instance, a conserved lysine is replaced by an arginine), which has historically led to the classification of KSR1 as a pseudokinase. Despite this, under certain experimental conditions, residual kinase activity has been observed, suggesting that the CA5 domain retains some functional capacity for phosphotransfer (zhang2014identificationofksr1 pages 42-46, zhang2014identificationofksr1 pages 229-230). In addition to these core regions, KSR1 contains a coiled coil–sterile α motif (CC-SAM) domain that is crucial for its translocation to the plasma membrane in response to growth factor stimulation, thereby facilitating the assembly of the Raf/MEK/ERK complex (lavoie2018mekdrivesbraf pages 4-6, zhang2014identificationofksr1 pages 42-46). Structural models comparing KSR1 with prototypical eukaryotic protein kinases such as the mouse cAMP-dependent protein kinase alpha subunit underscore the overall conserved fold despite unique regulatory adaptations (paniagua2022ksrinducesras‐independent pages 4-5).

6. Regulation  
The activity of KSR1 is tightly regulated by multiple mechanisms that modulate its localization, interaction with binding partners, and potential catalytic output. Foremost among these regulatory strategies is reversible phosphorylation. Specific serine residues on KSR1 are phosphorylated by upstream kinases, leading to the binding of 14-3-3 proteins that sequester KSR1 in the cytosol; this interaction prevents premature or inappropriate assembly of the MAPK signaling complex. Upon stimulation by growth factors, such as epidermal growth factor (EGF) or under conditions involving inflammatory mediators like tumor necrosis factor α (TNFα) and ceramide, KSR1 undergoes dephosphorylation events, which trigger dissociation from 14-3-3 proteins and promote its translocation to the plasma membrane. This translocation is critical for the nucleation of a signaling complex comprising Raf, MEK, and ERK, as well as for the allosteric activation of BRAF via MEK binding (zhang2014identificationofksr1 pages 46-49, neilsen2017ksrasa pages 4-6). Furthermore, the constitutive interaction between KSR1 and MEK serves as a platform that not only brings the MAPK cascade components into proximity but also induces conformational changes necessary for heterodimerization with Raf proteins (neilsen2017ksrasa pages 14-15, paniagua2022ksrinducesras‐independent pages 1-2). In addition, certain studies have noted that KSR1 can undergo autophosphorylation in vitro, though the physiological relevance of this self-modification remains under active investigation (zhang2014identificationofksr1 pages 49-52, dougherty2009ksr2isa pages 13-19).

7. Function  
KSR1 functions predominantly as a molecular scaffold in the Ras-Raf-MAPK signaling cascade, playing a crucial role in the coordination and amplification of extracellular signals. By assembling essential kinases—including Raf, MEK, and ERK—KSR1 ensures the precise spatial and temporal activation of the downstream mitogen-activated protein kinase (MAPK) pathway. In its scaffolding role, KSR1 aids in the allosteric activation of BRAF through a MEK-dependent mechanism; when KSR1 binds to MEK1/2, it facilitates heterodimerization with BRAF, thereby promoting BRAF-mediated phosphorylation of MEK and subsequent activation of ERK (dougherty2009ksr2isa pages 1-2, neilsen2017ksrasa pages 3-4, zhang2014identificationofksr1 pages 241-242). Although its intrinsic kinase activity is complex and remains a subject of debate, evidence from in vitro studies indicates that KSR1 can autophosphorylate and phosphorylate key signaling components such as Raf-1, contributing further to the regulation of the MAPK cascade (zhang2014identificationofksr1 pages 49-52, zhang2014identificationofksr1 pages 232-233). The biological roles of KSR1 extend to the regulation of cell proliferation, differentiation, and oncogenesis. Tissue-specific isoforms, including a brain-specific form identified as B-KSR1, point to additional functions in neuronal signaling and central nervous system development (muller2000identificationofbksr1 pages 7-9, neilsen2017ksrasa pages 1-3). In the context of cancer, particularly Ras-dependent tumors, KSR1 plays an integral role by modulating signal strength and duration through its scaffold functions, which makes it an attractive target for therapeutic intervention in malignancies such as pancreatic, lung, and breast cancers (stebbing2015ksr1regulatesbrca1 pages 1-5, neilsen2017ksrasa pages 15-18).

8. Other Comments  
Despite early classification as a pseudokinase due to notable substitutions in its kinase domain, emerging experimental evidence supports a scenario in which KSR1 may exhibit context-dependent catalytic activity in addition to its primary scaffolding function. This dual role is underscored by studies reporting ATP binding–dependent autophosphorylation and substrate phosphorylation that can be modulated by external signals such as TNFα, ceramide, and EGF (zhang2014identificationofksr1 pages 49-52). In light of these findings, pharmacological strategies have been explored that aim to modulate KSR1 activity by targeting its ATP-binding site or by stabilizing its inactive conformation; small molecules that interfere with KSR1’s function could potentially attenuate aberrant Ras-dependent signaling in cancer (dar2016smallmoleculestabilization pages 6-7, stebbing2015ksr1regulatesbrca1 pages 8-12). Moreover, the conservation of KSR1’s scaffolding mechanism across species, along with its tissue-specific isoforms, suggests that while it plays a central role in the propagation of mitogenic signals, it may also be exploited in non-proliferative contexts such as neuronal differentiation. Aberrant regulation or mutations affecting KSR1 function have been implicated in various pathologies, notably in oncogenesis, positioning KSR1 as both a biomarker and a potential drug target in Ras-dependent cancer therapies (zhang2014identificationofksr1 pages 180-186, neilsen2017ksrasa pages 1-3).

References

1. (dougherty2009ksr2isa pages 1-2): Michele K. Dougherty, Daniel A. Ritt, Ming Zhou, Suzanne I. Specht, Daniel M. Monson, Timothy D. Veenstra, and Deborah K. Morrison. Ksr2 is a calcineurin substrate that promotes erk cascade activation in response to calcium signals. Molecular cell, 34 6:652-62, Jun 2009. URL: https://doi.org/10.1016/j.molcel.2009.06.001, doi:10.1016/j.molcel.2009.06.001. This article has 154 citations and is from a highest quality peer-reviewed journal.

2. (neilsen2017ksrasa pages 3-4): Beth K. Neilsen, Danielle E. Frodyma, Robert E. Lewis, and Kurt W. Fisher. Ksr as a therapeutic target for ras-dependent cancers. Expert Opinion on Therapeutic Targets, 21:499-509, Apr 2017. URL: https://doi.org/10.1080/14728222.2017.1311325, doi:10.1080/14728222.2017.1311325. This article has 40 citations and is from a peer-reviewed journal.

3. (zhang2014identificationofksr1 pages 229-230): Hua-Ying Zhang. Identification of ksr1 as a novel target and decoding tyrosine kinase proteome in breast cancer. Unknown journal, Apr 2014. URL: https://doi.org/10.25560/34315, doi:10.25560/34315. This article has 0 citations.

4. (zhang2014identificationofksr1 pages 42-46): Hua-Ying Zhang. Identification of ksr1 as a novel target and decoding tyrosine kinase proteome in breast cancer. Unknown journal, Apr 2014. URL: https://doi.org/10.25560/34315, doi:10.25560/34315. This article has 0 citations.

5. (dar2016smallmoleculestabilization pages 6-7): Neil S. Dhawan, Alex P. Scopton, and Arvin C. Dar. Small molecule stabilization of the ksr inactive state antagonizes oncogenic ras signalling. Nature, 537:112-116, Aug 2016. URL: https://doi.org/10.1038/nature19327, doi:10.1038/nature19327. This article has 114 citations and is from a highest quality peer-reviewed journal.

6. (dougherty2009ksr2isa pages 13-19): Michele K. Dougherty, Daniel A. Ritt, Ming Zhou, Suzanne I. Specht, Daniel M. Monson, Timothy D. Veenstra, and Deborah K. Morrison. Ksr2 is a calcineurin substrate that promotes erk cascade activation in response to calcium signals. Molecular cell, 34 6:652-62, Jun 2009. URL: https://doi.org/10.1016/j.molcel.2009.06.001, doi:10.1016/j.molcel.2009.06.001. This article has 154 citations and is from a highest quality peer-reviewed journal.

7. (lavoie2018mekdrivesbraf pages 4-6): Hugo Lavoie, Malha Sahmi, Pierre Maisonneuve, Sara A. Marullo, Neroshan Thevakumaran, Ting Jin, Igor Kurinov, Frank Sicheri, and Marc Therrien. Mek drives braf activation through allosteric control of ksr proteins. Nature, 554:549-553, Feb 2018. URL: https://doi.org/10.1038/nature25478, doi:10.1038/nature25478. This article has 144 citations and is from a highest quality peer-reviewed journal.

8. (muller2000identificationofbksr1 pages 1-2): Jürgen Müller, Angela M. Cacace, W. Ernest Lyons, Carolyn B. McGill, and Deborah K. Morrison. Identification of b-ksr1, a novel brain-specific isoform of ksr1 that functions in neuronal signaling. Molecular and Cellular Biology, 20:5529-5539, Aug 2000. URL: https://doi.org/10.1128/mcb.20.15.5529-5539.2000, doi:10.1128/mcb.20.15.5529-5539.2000. This article has 133 citations and is from a domain leading peer-reviewed journal.

9. (muller2000identificationofbksr1 pages 7-9): Jürgen Müller, Angela M. Cacace, W. Ernest Lyons, Carolyn B. McGill, and Deborah K. Morrison. Identification of b-ksr1, a novel brain-specific isoform of ksr1 that functions in neuronal signaling. Molecular and Cellular Biology, 20:5529-5539, Aug 2000. URL: https://doi.org/10.1128/mcb.20.15.5529-5539.2000, doi:10.1128/mcb.20.15.5529-5539.2000. This article has 133 citations and is from a domain leading peer-reviewed journal.

10. (neilsen2017ksrasa pages 1-3): Beth K. Neilsen, Danielle E. Frodyma, Robert E. Lewis, and Kurt W. Fisher. Ksr as a therapeutic target for ras-dependent cancers. Expert Opinion on Therapeutic Targets, 21:499-509, Apr 2017. URL: https://doi.org/10.1080/14728222.2017.1311325, doi:10.1080/14728222.2017.1311325. This article has 40 citations and is from a peer-reviewed journal.

11. (neilsen2017ksrasa pages 14-15): Beth K. Neilsen, Danielle E. Frodyma, Robert E. Lewis, and Kurt W. Fisher. Ksr as a therapeutic target for ras-dependent cancers. Expert Opinion on Therapeutic Targets, 21:499-509, Apr 2017. URL: https://doi.org/10.1080/14728222.2017.1311325, doi:10.1080/14728222.2017.1311325. This article has 40 citations and is from a peer-reviewed journal.

12. (neilsen2017ksrasa pages 15-18): Beth K. Neilsen, Danielle E. Frodyma, Robert E. Lewis, and Kurt W. Fisher. Ksr as a therapeutic target for ras-dependent cancers. Expert Opinion on Therapeutic Targets, 21:499-509, Apr 2017. URL: https://doi.org/10.1080/14728222.2017.1311325, doi:10.1080/14728222.2017.1311325. This article has 40 citations and is from a peer-reviewed journal.

13. (neilsen2017ksrasa pages 21-22): Beth K. Neilsen, Danielle E. Frodyma, Robert E. Lewis, and Kurt W. Fisher. Ksr as a therapeutic target for ras-dependent cancers. Expert Opinion on Therapeutic Targets, 21:499-509, Apr 2017. URL: https://doi.org/10.1080/14728222.2017.1311325, doi:10.1080/14728222.2017.1311325. This article has 40 citations and is from a peer-reviewed journal.

14. (neilsen2017ksrasa pages 4-6): Beth K. Neilsen, Danielle E. Frodyma, Robert E. Lewis, and Kurt W. Fisher. Ksr as a therapeutic target for ras-dependent cancers. Expert Opinion on Therapeutic Targets, 21:499-509, Apr 2017. URL: https://doi.org/10.1080/14728222.2017.1311325, doi:10.1080/14728222.2017.1311325. This article has 40 citations and is from a peer-reviewed journal.

15. (paniagua2022ksrinducesras‐independent pages 1-2): Guillem Paniagua, Harrys K.C. Jacob, Oksana Brehey, Sara García‐Alonso, Carmen G. Lechuga, Tirso Pons, Monica Musteanu, Carmen Guerra, Matthias Drosten, and Mariano Barbacid. Ksr induces ras‐independent mapk pathway activation and modulates the efficacy of kras inhibitors. Molecular Oncology, 16:3066-3081, Apr 2022. URL: https://doi.org/10.1002/1878-0261.13213, doi:10.1002/1878-0261.13213. This article has 24 citations and is from a peer-reviewed journal.

16. (paniagua2022ksrinducesras‐independent pages 4-5): Guillem Paniagua, Harrys K.C. Jacob, Oksana Brehey, Sara García‐Alonso, Carmen G. Lechuga, Tirso Pons, Monica Musteanu, Carmen Guerra, Matthias Drosten, and Mariano Barbacid. Ksr induces ras‐independent mapk pathway activation and modulates the efficacy of kras inhibitors. Molecular Oncology, 16:3066-3081, Apr 2022. URL: https://doi.org/10.1002/1878-0261.13213, doi:10.1002/1878-0261.13213. This article has 24 citations and is from a peer-reviewed journal.

17. (zhang2014identificationofksr1 pages 232-233): Hua-Ying Zhang. Identification of ksr1 as a novel target and decoding tyrosine kinase proteome in breast cancer. Unknown journal, Apr 2014. URL: https://doi.org/10.25560/34315, doi:10.25560/34315. This article has 0 citations.

18. (zhang2014identificationofksr1 pages 241-242): Hua-Ying Zhang. Identification of ksr1 as a novel target and decoding tyrosine kinase proteome in breast cancer. Unknown journal, Apr 2014. URL: https://doi.org/10.25560/34315, doi:10.25560/34315. This article has 0 citations.

19. (zhang2014identificationofksr1 pages 46-49): Hua-Ying Zhang. Identification of ksr1 as a novel target and decoding tyrosine kinase proteome in breast cancer. Unknown journal, Apr 2014. URL: https://doi.org/10.25560/34315, doi:10.25560/34315. This article has 0 citations.

20. (zhang2014identificationofksr1 pages 49-52): Hua-Ying Zhang. Identification of ksr1 as a novel target and decoding tyrosine kinase proteome in breast cancer. Unknown journal, Apr 2014. URL: https://doi.org/10.25560/34315, doi:10.25560/34315. This article has 0 citations.

21. (stebbing2015ksr1regulatesbrca1 pages 1-5): Justin Stebbing, Hua Zhang, Yichen Xu, L. C. Lit, Andrew R. Green, A. Grothey, Y. Lombardo, M. Periyasamy, Kevin Blighe, Wu Zhang, Jacqui A. Shaw, Ian O. Ellis, H. Lenz, and G. Giamas. Ksr1 regulates brca1 degradation and inhibits breast cancer growth. Oncogene, 34:2103-2114, Jun 2015. URL: https://doi.org/10.1038/onc.2014.129, doi:10.1038/onc.2014.129. This article has 23 citations and is from a domain leading peer-reviewed journal.

22. (stebbing2015ksr1regulatesbrca1 pages 8-12): Justin Stebbing, Hua Zhang, Yichen Xu, L. C. Lit, Andrew R. Green, A. Grothey, Y. Lombardo, M. Periyasamy, Kevin Blighe, Wu Zhang, Jacqui A. Shaw, Ian O. Ellis, H. Lenz, and G. Giamas. Ksr1 regulates brca1 degradation and inhibits breast cancer growth. Oncogene, 34:2103-2114, Jun 2015. URL: https://doi.org/10.1038/onc.2014.129, doi:10.1038/onc.2014.129. This article has 23 citations and is from a domain leading peer-reviewed journal.

23. (zhang2014identificationofksr1 pages 180-186): Hua-Ying Zhang. Identification of ksr1 as a novel target and decoding tyrosine kinase proteome in breast cancer. Unknown journal, Apr 2014. URL: https://doi.org/10.25560/34315, doi:10.25560/34315. This article has 0 citations.